New targeted drug shows promise for Hard-to-Treat stomach cancers
Disease control
Terminated
This early-phase trial tested a new drug called EO-3021, which targets a protein (CLDN18.2) found on some cancer cells. The study included 88 adults with advanced stomach or gastrointestinal cancers that had not responded to standard treatments. Participants received EO-3021 alon…
Phase: PHASE1 • Sponsor: Elevation Oncology • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC